Comprehensive transcriptome, miRNA and kinome profiling identifies new treatment options for personalized lung cancer therapy.

ABSTRACT:

Background

Basic research identified oncogenic driver mutations in lung cancer (LC). However, <10% of patients carry driver mutations. Thus, most patients are not recommended for first-line kinase inhibitor (KI)-based therapies. Through enabling technologies and bioinformatics, we gained deep insight into patient-specific signalling networks which permitted novel KI-based treatment options in LC.

Methods

We performed molecular pathology, transcriptomics and miRNA profiling across 95 well-characterized LC patients. We confirmed results based on cross-linked immunoprecipitation-sequencing data, and used N = 524 adeno- and 497 squamous cell carcinomas as validation sets. We employed the PamGene platform to identify aberrant kinases, validated the results by evaluating independe

SUBMITTER: Zhong S 

PROVIDER: S-EPMC11850761 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature